Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05819112 · ClinicalTrials.gov registry record
A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness
A clinical trial, sponsored by Sanofi.
- Terminated
- Registry status
- 14,799
- Enrollment target
NCT05819112: Clinical Trial study, sponsored by Sanofi.
NCT05819112 is a clinical trial that was terminated before completion, run by Sanofi. The registered enrollment target is 14,799 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05819112 was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- 14,799 participants
- Enrollment target
Study Summary
Venous Thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is associated with an increase in risk of mortality and long-term disability and is a major contributor to global disease burden. Participants hospitalized with an acute medical illness are at increased risk of VTE. This study a non-interventional study which analyzes data already collected in the Optum US clinical database. Its aim is to compare conventional versus extended duration prophylaxis with enoxaparin on the incidence of VTE and bleeding events in participants hospitalized for acute medical illness. The first date of enoxaparin treatment will be the index date.
Primary Outcome
VTE event will be identified via an algorithm based on the International Classification of Disease-10th revision and 9th revision (ICD-10 and ICD-9) codes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,799 participants |
| Start Date | 2023-04-25 |
| Est. Completion | 2023-12-15 |
Why NCT05819112 stopped before completion
NCT05819112 is an observational study that tracks outcomes without assigning an intervention. Its 14,799 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05819112 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05819112 about?
NCT05819112 is a clinical study titled "A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness". Venous Thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is associated with an increase in risk of mortality and long-term disability and is a major contributor to global disease burden. Participants hospitalized with an acute medical illness are at increased r...
What is the current status of trial NCT05819112?
This trial is currently terminated. The enrollment target is 14,799 participants. The study started on 2023-04-25. Estimated completion is 2023-12-15.
Who is sponsoring clinical trial NCT05819112?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06849869 · 14,820 participants · NA
Collaborative Care Model for Perinatal Wellness Support Services - Population-Level Equity-Centered Systems Change
- NCT05359016 · 14,600 participants · NA
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
- NCT00857922 · 15,000 participants
Neurosciences Research Repository
- NCT01137643 · 15,000 participants
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI